The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free treatment for patients with EGFR-mutated non-small cell lung cancer across all ...

Older adults living with heart failure with preserved ejection fraction (HFpEF) are frequently labeled as having chronic ...

A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

Even "normal" kidney test results may mask hidden risks if theyre unusually low for your age and sex, signaling higher ...

Kidney disease often creeps in silently, and many patients aren’t diagnosed until major damage is already done. New research ...

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division.

Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious ...

As smoking rates fall, lung cancer in never-smokers (LCINS) represents an increasing share of lung cancer diagnoses. These cancers are frequently ...

A new international study has cautioned that kidney test results labelled as “normal” may still conceal early signs of ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.